BioTime Will Have to Compete for California Cash for Geron's Dormant Clinical Trial
The California stem cell agency said today it does not plan to reactivate the $25 million loan to assist in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.
Kevin McCormack, senior director for public communications for the agency, said BioTime will have to compete in an upcoming award round …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.